Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The immune modulator Pomalyst led to remission in two thirds of people with AIDS-related KS.
Th1-Th2 “shift” rears its ugly head
Keytruda may prolong survival compared with standard therapy.
Study suggests immune-based cancer therapies might be particularly beneficial for HIV-positive people.
Prestigious prize goes to researchers who identified B cells and T cells and others who invented the HER2 targeted cancer therapy Herceptin.
Experts discuss rapid changes in cancer treatment and in the management of infections that can accompany these therapies.
Keytruda and Imfinzi were well tolerated and responses were similar to those seen in HIV-negative people.
Treatment with checkpoint inhibitors appears safe and effective for HIV-positive people.
An HIV immunotherapy method performs well in early safety trial.
Here are the HIV treatment news stories with the most views this year.
Treatment with Opdivo appears to work well for HIV-positive people in small study.
Researchers drew immune cells from people on effective HIV treatment, cultured the cells and reinfused 40 million of them.
Six out of nine patients experienced cancer remission with Opdivo or Keytruda.
A case study of a 51-year-old man treated for lung cancer reveals a promising avenue toward possibly curing the virus.
Checkpoint inhibitor study suggests new treatment options for patients long excluded from cancer immunotherapy clinical trials.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.